User:Mjelliott1975/Narrow Specific Kinase Inhibitors (NSKIs)

Narrow Spectrum Kinase Inhibitors (NSKIs) are similar to protein kinase inhibitors except that they target a far narrower range of kinases, which act as key signaling molecules in inflammatory cells. The inhibition of narrow specific kinase combinations drives potent inhibitory effects in a wide range of cells, a quality which makes NSKIs highly effective in treating inflammatory illness.

Due to these properties NSKIs have a range of applications in modulating immune system activity both innate and adaptive.

The body's mucosal surface cells retain NSKIs effectively after administration, meaning that they remain active on a longer basis than typical protein kinase inhibitors without the need for re-administration. The residual presence of the compound in the circulatory system is lower than with other inhibitors, meaning that the use of NSKIs is safer and carries less risk of negative side effects than similar protein kinase molecules. As a result NSKIs are being viewed by many in the life sciences industry as a potential replacement for traditional protein kinase inhibitors.

Topical/local delivery of NSKIs results in :

• Improved efficacy in cellular and in vivo inflammation models compared to selective kinase inhibitors.

• Efficacy equivalent to or better than cyclosporine, corticosteroids and anti-TNFa in animal models of inflammatory disease.

• Efficacy in steroid-insensitive inflammation in vitro and in vivo.

The development of NSKIs has revolutionary implications for the treatment of cancer and could bring about the end of debilitating side effects for patients undergoing chemotherapy.